Immunogenicity and safety at twelve months of fractional and standard BNT162b2 booster doses in adults primed with ChAdOx1-S, BBIBP-CorV, or Gam-COVID-Vac in Mongolia: a randomised controlled trial.

Saved in:
Bibliographic Details
Title: Immunogenicity and safety at twelve months of fractional and standard BNT162b2 booster doses in adults primed with ChAdOx1-S, BBIBP-CorV, or Gam-COVID-Vac in Mongolia: a randomised controlled trial.
Authors: Batmunkh T; National Centre for Communicable Diseases, Ulaanbaatar, Mongolia., Neal EFG; Infection, Immunity, and Global Health, Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, Australia; Department of Paediatrics, The University of Melbourne, Parkville, Australia. Electronic address: eleanor.neal@mcri.edu.au., Amraa O; National Centre for Communicable Diseases, Ulaanbaatar, Mongolia., Mazarakis N; Infection, Immunity, and Global Health, Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, Australia; Department of Paediatrics, The University of Melbourne, Parkville, Australia., Altangerel B; Onoshmed Laboratory, Ulaanbaatar, Mongolia., Avaa N; Onoshmed Laboratory, Ulaanbaatar, Mongolia., Batbayar L; Sukhbaatar District Health Centre, Ulaanbaatar, Mongolia., Batsukh K; General Laboratory of Clinical Pathology, First Central Hospital of Mongolia, Ulaanbaatar, Mongolia., Bright K; Infection, Immunity, and Global Health, Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, Australia., Burentogtokh T; General Laboratory of Clinical Pathology, First Central Hospital of Mongolia, Ulaanbaatar, Mongolia., Do LAH; Infection, Immunity, and Global Health, Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, Australia; Department of Paediatrics, The University of Melbourne, Parkville, Australia., Dorj G; Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia., Hart JD; Infection, Immunity, and Global Health, Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, Australia; Department of Paediatrics, The University of Melbourne, Parkville, Australia., Jamiyandorj O; City Health Department, Ulaanbaatar, Mongolia., Javkhlantugs K; Bayangol District Health Centre, Ulaanbaatar, Mongolia., Jigjidsuren S; General Laboratory of Clinical Pathology, First Central Hospital of Mongolia, Ulaanbaatar, Mongolia., Justice F; Infection, Immunity, and Global Health, Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, Australia., Li S; Infection, Immunity, and Global Health, Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, Australia., Mashbaatar K; National Centre for Communicable Diseases, Ulaanbaatar, Mongolia., Moore KA; Infection, Immunity, and Global Health, Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, Australia., Namjil N; Onoshmed Laboratory, Ulaanbaatar, Mongolia., Nguyen CD; Infection, Immunity, and Global Health, Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, Australia., Ochirbat B; National Centre for Communicable Diseases, Ulaanbaatar, Mongolia., Surenjav U; National Centre for Public Health, Ulaanbaatar, Mongolia., Thomson H; Infection, Immunity, and Global Health, Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, Australia., Tsolmon B; National Centre for Communicable Diseases, Ulaanbaatar, Mongolia; Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia., Licciardi PV; Infection, Immunity, and Global Health, Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, Australia; Department of Paediatrics, The University of Melbourne, Parkville, Australia., von Mollendorf C; Infection, Immunity, and Global Health, Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, Australia; Department of Paediatrics, The University of Melbourne, Parkville, Australia., Mulholland K; Infection, Immunity, and Global Health, Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, Australia.
Source: Vaccine [Vaccine] 2025 Nov 14; Vol. 66, pp. 127840. Date of Electronic Publication: 2025 Oct 09.
Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Equivalence Trial
Journal Info: Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8406899 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2518 (Electronic) Linking ISSN: 0264410X NLM ISO Abbreviation: Vaccine Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1873-2518
DOI:10.1016/j.vaccine.2025.127840